Top Page
Judges Scientific
(LSE:JDG)
Judges Scientific (JDG) vs. iShares MSCI United Kingdom ETF (EWC)
Judges Scientific Business Overview & Revenue Model
Judges Scientific Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 133.60M | 136.10M | 113.21M | 91.29M | 79.86M |
| Gross Profit | 92.00M | 93.60M | 21.01M | 15.34M | 10.02M |
| EBITDA | 30.90M | 35.60M | 29.00M | 20.33M | 15.17M |
| Net Income | 10.40M | 9.50M | 12.50M | 12.68M | 8.22M |
Balance Sheet | |||||
| Total Assets | 205.10M | 183.50M | 185.79M | 88.98M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 17.90M | 13.70M | 20.83M | 18.41M | 15.52M |
| Total Debt | 73.60M | 65.30M | 59.95M | 21.32M | 26.37M |
| Total Liabilities | 117.90M | 100.90M | 131.33M | 45.58M | 48.98M |
| Stockholders Equity | 86.90M | 82.40M | 54.24M | 42.78M | 32.19M |
Cash Flow | |||||
| Free Cash Flow | 22.10M | 20.60M | 12.33M | 13.44M | 10.53M |
| Operating Cash Flow | 28.50M | 26.50M | 20.22M | 16.89M | 11.79M |
| Investing Cash Flow | -22.60M | -25.90M | -51.11M | -5.21M | -12.67M |
| Financing Cash Flow | -1.40M | -7.60M | 33.21M | -8.81M | 2.34M |
Judges Scientific Technical Analysis
Judges Scientific Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | 2.56B | 31.09 | ― | 1.59% | 3.15% | -13.57% | |
71 Outperform | 562.52M | 23.19 | 7.99% | 2.13% | -3.23% | 58.34% | |
63 Neutral | 4.06B | 69.89 | 16.89% | 1.86% | 0.07% | -78.33% | |
63 Neutral | £422.87M | 38.41 | 12.24% | 1.67% | 5.46% | -26.44% | |
61 Neutral | 155.64M | 28.44 | -5.88% | 2.30% | 1.74% | 359.50% | |
55 Neutral | 93.79M | 183.33 | 0.83% | 1.52% | -23.42% | -94.25% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
Judges Scientific Corporate Events
Judges Scientific plc announced that several of its key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director, have purchased ordinary shares in the company through the Share Incentive Plan. This move, conducted on the London Stock Exchange’s AIM Market, signifies a strong vote of confidence from the management in the company’s future prospects and aligns their interests with those of the shareholders.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc announced a ‘Bed and ISA’ transaction involving CEO David Cicurel and his spouse, where they sold and immediately repurchased a total of 625 ordinary shares into their ISAs. This transaction did not alter Cicurel’s total beneficial interest in the company, which remains at 544,369 ordinary shares. The move reflects a strategic financial decision, maintaining the company’s operational stability and shareholder interests.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc announced that Charles Holroyd, a Non-Executive Director, has purchased 524 ordinary shares in the company, increasing his total holding to 7,747 shares, which represents approximately 0.12% of the company’s total issued share capital. This transaction underscores the confidence of the company’s leadership in its strategic direction and potential for growth, reinforcing its position in the scientific instrument sector and signaling positive implications for stakeholders.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific announced that its Chief Financial Officer, Brad Ormsby, and Non-Executive Chairman, Ralph Elman, have purchased ordinary shares in the company through an automatic dividend reinvestment program. This transaction, conducted on the London Stock Exchange’s AIM Market, reflects the company’s ongoing strategy to enhance shareholder value through organic growth and dividends. The acquisition of shares by key executives may signal confidence in the company’s future prospects and stability, potentially impacting investor sentiment positively.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc reported that its trading performance for the first half of 2025 was significantly impacted by challenges in the US market, including reduced federal research funding and specific market and product issues. Despite a 7% increase in organic revenue driven by a coring expedition in Japan, the Group’s overall performance fell short of expectations, particularly in North America. The company anticipates lower-than-expected earnings per share for the full year but maintains a healthy order book and strong financial position, which supports its strategy for sustainable shareholder returns.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan involving key executives including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. The transactions, conducted on July 7, 2025, at the London Stock Exchange’s AIM Market, reflect a strategic move to align the interests of the company’s leadership with its shareholders, potentially strengthening stakeholder confidence and market positioning.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific, a company involved in scientific instrumentation, has announced an increase in its total issued share capital to 6,647,952 Ordinary shares as of June 30, 2025. This change impacts the voting rights structure, with each share carrying one vote, and is relevant for shareholders calculating their notifiable interest under the Disclosure and Transparency Rules.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific has appointed Rik Armitage as Group Acquisitions Executive to support its strategy of expanding its pipeline of potential deals and maintaining a disciplined acquisition process. Armitage, with over thirty years of experience in strategy and M&A, will join the recently formed Executive Committee, bringing expertise from his previous roles at Oxford Instruments and Chemring Group, which are expected to enhance Judges Scientific’s buy and build growth strategy.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan involving several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. Each transaction was conducted on the London Stock Exchange, AIM Market, at a price of 7870.0p per share, reflecting the company’s commitment to aligning management interests with shareholder value.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific announced the acquisition of 28 ordinary shares at a price of 7875p per share, which have been allocated to employees under the company’s reward scheme. This move reflects the company’s ongoing strategy to enhance shareholder value through sustainable profit generation, debt reduction, organic growth, and dividends.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific announced the successful passing of all resolutions at their recent Annual General Meeting, including the approval of financial statements, remuneration reports, and director re-elections. Notably, over 20% of shareholders opposed the re-election of Ralph Elman as a director, prompting the board to engage with shareholders for feedback. This outcome highlights the company’s commitment to stakeholder engagement and governance, potentially impacting its strategic direction and investor relations.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £10600.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc announced the acquisition of 655 ordinary shares at a price of 7820p per share, which were immediately allocated to employees as part of the company’s reward scheme. This move reflects the company’s ongoing commitment to rewarding its employees and maintaining a strong operational framework, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.